Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis
Journal of Crohn's and Colitis · 30.12.2023 · 17 (12) · 2033-2036
DOI: 10.1093/ecco-jcc/jjad115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 09.07.2023. Verfasst von Robert Gilmore und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Mater Hospital, Brisbane, Australia. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims Acute severe ulcerative colitis [ASUC] is a medical emergency treated with intravenous steroids followed by infliximab or cyclosporin in the case of steroid failure with emergent colectomy required in refractory or severe cases. Case series have reported on the effectiveness of tofacitinib for refractory disease, but data regarding the effectiveness of upadacitinib in this setting have not been previously reported. We describe the use of upadacitinib therapy for steroid-refractory ASUC in patients with prior loss of response to infliximab.
Methods
Six patients who received upadacitinib for steroid-refractory ASUC were identified at two Australian tertiary inflammatory bowel disease centres. Patients were followed for up to 16 weeks after discharge with clinical, biochemical and intestinal ultrasound [IUS] outcomes.
Results
All six patients demonstrated clinical response to upadacitinib induction during their inpatient admission. Four patients achieved corticosteroid-free clinical remission by week 8, including complete resolution of rectal bleeding and transmural healing assessed by IUS, and sustained clinical remission at week 16. One patient proceeded to colectomy at week 15 due to refractory disease. No adverse events directly attributable to upadacitinib were identified.
Conclusions
Upadacitinib may have a role as a safe and effective salvage therapy for steroid-refractory ASUC in patients who have previously failed to respond to infliximab therapy. Prospective studies are required to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Mater Hospital, Brisbane, Australia.
- Department of Medicine, University of Queensland, Brisbane, Australia.
- Mater Research Institute, Brisbane, Australia.
- Mater Private Hospital, Brisbane, Australia.
ORCID-Profile: Robert Gilmore
Zitieren
APA
Gilmore, R., Tan, W. L., Fernandes, R., An, Y. K., & Begun, J. (2023). Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 17(12), 2033-2036. https://doi.org/10.1093/ecco-jcc/jjad115
Vancouver
Gilmore R, Tan WL, Fernandes R, An YK, Begun J. Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis. Journal of Crohn's and Colitis. 2023;17(12):2033-2036. doi:10.1093/ecco-jcc/jjad115
BibTeX
@article{Gilmore2023,
author = {Gilmore, Robert and Tan, Wei Lian and Fernandes, Richard and An, Yoon-Kyo and Begun, Jakob},
title = {Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis},
journal = {Journal of Crohn's and Colitis},
year = {2023},
volume = {17},
number = {12},
pages = {2033--2036},
doi = {10.1093/ecco-jcc/jjad115}
}
EUVIMED